Talphera (NASDAQ:TLPH – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.14, Zacks reports.
Talphera Stock Performance
TLPH opened at $0.50 on Tuesday. Talphera has a 52-week low of $0.45 and a 52-week high of $1.27. The firm has a market cap of $8.43 million, a P/E ratio of -0.72 and a beta of 0.20. The business’s fifty day moving average is $0.61 and its 200-day moving average is $0.71.
Wall Street Analyst Weigh In
TLPH has been the subject of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Talphera in a research report on Tuesday. Rodman & Renshaw initiated coverage on shares of Talphera in a report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 price objective for the company. Finally, RODMAN&RENSHAW raised shares of Talphera to a “strong-buy” rating in a report on Tuesday, January 28th.
About Talphera
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Read More
- Five stocks we like better than Talphera
- Investing in Construction Stocks
- Is Now the Right Time to Invest in a Natural Gas ETF?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Amprius Market Gets Amped Up on Growth Outlook
- Dividend Payout Ratio Calculator
- ETFs With the Best Returns of 2025: Gold and Silver Miners on Top
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
